Rapid Micro Biosystems (RPID) Projected to Post Quarterly Earnings on Friday

Rapid Micro Biosystems (NASDAQ:RPID) is expected to post its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect Rapid Micro Biosystems to post earnings of ($0.23) per share and revenue of $10.9330 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 8:30 AM ET.

Rapid Micro Biosystems Stock Performance

NASDAQ RPID opened at $4.39 on Thursday. The stock has a market cap of $194.56 million, a PE ratio of -4.35 and a beta of 1.38. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 4.23. The firm has a 50-day moving average of $3.72 and a 200-day moving average of $3.43. Rapid Micro Biosystems has a 52-week low of $1.86 and a 52-week high of $4.94.

Analyst Upgrades and Downgrades

Several research firms have recently commented on RPID. Wall Street Zen raised Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $8.00.

Insider Buying and Selling

In other news, CFO Sean M. Wirtjes sold 17,254 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $3.92, for a total value of $67,635.68. Following the sale, the chief financial officer directly owned 563,674 shares in the company, valued at approximately $2,209,602.08. This trade represents a 2.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Robert G. Jr. Spignesi sold 38,327 shares of Rapid Micro Biosystems stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $3.89, for a total transaction of $149,092.03. Following the sale, the chief executive officer directly owned 1,187,770 shares in the company, valued at $4,620,425.30. This trade represents a 3.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 214,700 shares of company stock worth $873,906 in the last ninety days. 29.96% of the stock is owned by insiders.

Hedge Funds Weigh In On Rapid Micro Biosystems

Several institutional investors and hedge funds have recently added to or reduced their stakes in RPID. Geode Capital Management LLC grew its stake in shares of Rapid Micro Biosystems by 1.6% during the second quarter. Geode Capital Management LLC now owns 204,079 shares of the company’s stock worth $704,000 after buying an additional 3,143 shares during the last quarter. American Century Companies Inc. grew its position in Rapid Micro Biosystems by 46.1% during the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after acquiring an additional 5,341 shares during the last quarter. Renaissance Technologies LLC grew its position in Rapid Micro Biosystems by 4.9% during the 4th quarter. Renaissance Technologies LLC now owns 115,627 shares of the company’s stock worth $335,000 after acquiring an additional 5,440 shares during the last quarter. Susquehanna International Group LLP increased its holdings in Rapid Micro Biosystems by 12.6% in the 3rd quarter. Susquehanna International Group LLP now owns 58,387 shares of the company’s stock worth $195,000 after purchasing an additional 6,528 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Rapid Micro Biosystems by 37.8% in the third quarter. Dimensional Fund Advisors LP now owns 55,642 shares of the company’s stock valued at $186,000 after purchasing an additional 15,255 shares during the last quarter. Institutional investors own 52.60% of the company’s stock.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.